

Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028

<https://marketpublishers.com/r/G609C48C5E32EN.html>

Date: February 2023

Pages: 150

Price: US\$ 3,000.00 (Single User License)

ID: G609C48C5E32EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028 Report highlights:

Global LAG-3 Inhibitor Drug Market Opportunity Assessment

Number Of LAG-3 Inhibitor Drugs In Market: 1 Drug

Approved LAG-3 Inhibitor Drug Dosage, Patent & Pricing Insight

Number Of LAG-3 Inhibitor Drugs In Clinical Trials: > 35 Drugs

LAG-3 Inhibitor Drugs Clinical Trials Insight By Company, Country, Indication, & Phase

LAG-3 Targeted Therapy Approaches

Competitive Landscape: Company Financials & Anti LAG-3 Antibodies in Trials

Lymphocyte-activation gene 3 (LAG-3) is a protein which was discovered in 1990 and found to be expressed on the cell surfaces of NK cells, activated T cells, B cells and plasmacytoid dendritic cells. LAG-3 is an immune checkpoint and has been considered as a target for developing drugs and therapies for the treatment of cancer, chronic infectious diseases and autoimmune diseases. In spite of the research activities

spanning decades, it is believed that much of the knowledge about LAG-3, and especially those related to its mechanism of action, is still undiscovered. LAG-3 has potential as a therapeutic target for the management of several diseases, therefore it is essential to thoroughly investigate the protein and its functions to develop effective treatment strategies.

In last few decades, immune checkpoints have garnered interest of researchers as a result of which LAG-3 is probably the next most studied immune checkpoint after PD-1 and CTLA-4. Similar to the other immune checkpoint proteins, LAG-3 inhibits the function of cytotoxic cells after binding to its ligand, which is mainly the MHC class II molecule. Similarly, it also binds to the LSECtin, FGL1 and Galectin-3 as part of the MHC class II independent pathways, exerting additional immune suppressive effects. LAG-3 present on Treg cells also inhibits the proliferation of dendritic cells (DC). In another study, it was found that LAG-3 signaling downregulated the proliferation of NK cells. Therefore, with its effects inhibiting the proliferation and activation of a number of immune cells, LAG-3 develops an immunosuppressive environment, which fosters the proliferation and metastasis of cancer tumors. This property of LAG-3 has put it in limelight as a potential target for developing drugs and therapies directed towards the LAG-3.

Apart from cancer, LAG-3 is also said to have a role in the development of autoimmune disease and the induction of autoimmunity. In preclinical studies with non-obese diabetic (NOD) mouse models, the absence of LAG-3 was linked with a 100% occurrence of diabetes at an accelerated rate, which was otherwise delayed. The untapped proliferation of Treg cells in the absence of LAG-3 was the cause of for this. In another experiment, it was reported that the deficiency or inhibition of the LAG-3 increased the model's susceptibility to developing autoimmunity induced by mercury. Further research showed that LAG-3 works in sync with the PD-1 immune checkpoint to delay or decrease the possibility of the initiation of autoimmune diseases and that immune exhaustion is linked with a less severe autoimmune disease.

From these research studies it is obvious that inhibition of immune cells by LAG-3 is both friend and foe. In the case of cancer, suppression of the immune system is detrimental for the body but in others, unchecked growth of T cells has been linked with the development of autoimmune disease. The role of LAG-2 has been mainly studied in reference to cancer and many inhibitors have been developed and are being evaluated in clinical trials; however, studies analyzing its role in the development and progression of autoimmune diseases and infectious diseases is still lacking and there is a dearth of medications in the pipeline to address this problem.

As mentioned above, LAG-3 has a complex mechanism of action and researchers have not been able to fully understand its functions and its potential in the treatment of diseases. This calls for a more thorough research to understand the protein and its interactions and the extent to which these factors can be exploited to benefit human by treating disease. Future research also needs to focus on the effects of LAG-3 inhibition on other cells part from the conventional T cells.

Contents

1. INTRODUCTION TO LAG-3 INHIBITOR

- 1.1 Overview Of LAG-3 inhibitors
- 1.2 Mechanism of Action
- 1.3 LAG-3 Targeted Therapy Approaches
 - 1.3.1 Targeting LAG-3 With Fusion Proteins
 - 1.3.2 Targeting LAG-3 With Monoclonal Antibodies
 - 1.3.3 Targeting LAG-3 With Bispecific Antibodies

2. LAG-3 TARGETED THERAPY IN BY INDICATION

- 2.1 Cancer
- 2.2 Viral Infections
- 2.3 Autoimmune Diseases
- 2.4 Parkinson Disease

3. OPDUALAG – 1ST APPROVED LAG-3 INHIBITOR CLINICAL INSIGHT

4. OPDUALAG – 1ST APPROVED LAG-3 INHIBITOR COMMERCIAL INSIGHT

- 4.1 Overview & Patent Analysis
- 4.2 Pricing & Dosage Analysis
- 4.3 Sales Analysis

5. GLOBAL LAG-3 INHIBITOR MARKET

- 5.1 Current Market Overview
- 5.2 Market Opportunity Assessment

6. GLOBAL LAG-3 INHIBITOR CLINICAL TRIALS OVERVIEW

- 6.1 By Company
- 6.2 By Country
- 6.3 By Indication
- 6.4 By Patient Segment
- 6.5 By Phase

7. GLOBAL LAG-3 INHIBITOR CLINICAL TRIALS INSIGHT 2023 -2028

- 7.1 Research
- 7.2 Preclinical
- 7.3 Phase-I
- 7.4 Phase-I/II
- 7.5 Phase-II
- 7.6 Phase-II/III
- 7.7 Phase-III

8. GLOBAL LAG-3 INHIBITOR MARKET DYNAMICS

- 8.1 Market Drivers & Opportunities
- 8.2 Commercialization Challenges

9. GLOBAL LAG-3 INHIBITOR MARKET FUTURE OUTLOOK

10. COMPETITIVE LANDSCAPE

- 10.1 Abeome Corporation
- 10.2 ABL Bio
- 10.3 Agenus
- 10.4 Akeso Biopharma
- 10.5 AnaptysBio
- 10.6 Bristol-Myers Squibb
- 10.7 Cancer Research UK
- 10.8 F-Star Therapeutics
- 10.9 Immutep
- 10.10 Incyte Corporation
- 10.11 Innovent Biologics
- 10.12 Ligand Pharmaceuticals
- 10.13 Merck
- 10.14 Shanghai Fosun Pharmaceutical
- 10.15 Y-Biologics

List Of Figures

LIST OF FIGURES

Figure 1-1: LAG-3/MHC Class II Signaling Pathway

Figure 1-2: LAG-3 Inhibitor – Mechanism of Action

Figure 1-3: Binding Efficacy of Bispecific Antibodies

Figure 2-1: LAG-3 Signaling in Cancer Cell

Figure 2-2: LAG-3 on T Cells During HIV Infection

Figure 2-3: LAG-3 Associated Autoimmune Diseases

Figure 2-4: Implication of LAG-3 in PD Progression

Figure 2-5: Biomarker Potential of LAG-3 in Parkinson Disease

Figure 4-1: Opdualag – Years Of Approval

Figure 4-2: Opdualag – FDA Orphan & Priority Review Designation Year

Figure 4-3: Neo ReNi II Study – Estimated Starting & Ending Years

Figure 4-4: RELATIVITY-127 Study – Estimated Starting & Ending Years

Figure 4-5: US – Price Of 20ml Vial Of Opdualag (US\$), February, 2023

Figure 4-6: US/Global – Opdualag Quarterly Sales (US\$ Million), 2022

Figure 5-1: Global – Cancer Immunotherapy Market Size (US\$ Billion), 2023 - 2028

Figure 5-2: Global – LAG-3 Inhibitor Market Opportunity by 1% Cancer Immunotherapy Market (US\$ Billion), 2023 - 2028

Figure 5-3: Global – LAG-3 Inhibitor Market Opportunity by 2% Cancer Immunotherapy Market (US\$ Billion), 2023 - 2028

Figure 5-4: Global – LAG-3 Inhibitor Market Opportunity by 3% Cancer Immunotherapy Market (US\$ Billion), 2023 - 2028

Figure 5-5: Global – LAG-3 Inhibitor Market Opportunity by 4% Cancer Immunotherapy Market (US\$ Billion), 2023 - 2028

Figure 5-6: Global – LAG-3 Inhibitor Market Opportunity by 5% Cancer Immunotherapy Market (US\$ Billion), 2023 - 2028

Figure 5-7: Global – LAG-3 Inhibitor Market Opportunity by 6% Cancer Immunotherapy Market (US\$ Billion), 2023 - 2028

Figure 5-8: Global – LAG-3 Inhibitor Market Opportunity by 7% Cancer Immunotherapy Market (US\$ Billion), 2023 - 2028

Figure 5-9: Global – LAG-3 Inhibitor Market Opportunity by 8% Cancer Immunotherapy Market (US\$ Billion), 2023 - 2028

Figure 5-10: Global – LAG-3 Inhibitor Market Opportunity by 9% Cancer Immunotherapy Market (US\$ Billion), 2023 - 2028

Figure 5-11: Global – LAG-3 Inhibitor Market Opportunity by 10% Cancer Immunotherapy Market (US\$ Billion), 2023 - 2028

Figure 6-1: Global – LAG 3 Inhibitor Clinical Trials By Company, 2023 till 2028

Figure 6-2: Global – LAG 3 Inhibitor Clinical Trials By Country, 2023 till 2028

Figure 6-3: Global – LAG 3 Inhibitor Clinical Trials By Indication, 2023 till 2028

Figure 6-4: Global – LAG 3 Inhibitors Clinical Trials By Patient Segment, 2023 till 2028

Figure 6-5: Global – Number of LAG 3 Inhibitors In Clinical Trials By Phase, 2023 till 2028

Figure 8-1: LAG-3 Inhibitor Market Drivers & Opportunities

Figure 8-2: LAG-3 Inhibitor Market Challenges & Restraints

List Of Tables

LIST OF TABLES

Table 4-1: Maximum Infusion Volumes and Concentration Ranges By Patient Group

Table 4-2: Recommended Opdualag Dosage Modifications For Adverse Reactions

Table 10-1: Agenus – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight

Table 10-2: AnaptysBio – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight

Table 10-3: Bristol Myers Squibb – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight

Table 10-4: F-Star – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight

Table 10-5: Immutep – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight

Table 10-6: Incyte Corporation – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight

Table 10-7: Innovent Biologics – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight

Table 10-8: Ligand Pharmaceuticals – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight

Table 10-9: Merck KGaA – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight

Table 10-10: Shanghai Fosun Pharmaceutical – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight

I would like to order

Product name: Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/G609C48C5E32EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G609C48C5E32EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970